The Association of Triglyceride-Glucose (TyG) Index with Clinical Findings and Outcomes in COVID-19 Intensive Care Unit Patients
Abstract
Objectives: The association of COVID-19 with metabolic risk factors is a critical issue influencing disease progression and mortality. The triglyceride-glucose (TyG) index, a practical indicator of insulin resistance, holds value in the prognosis of cardiovascular diseases. In this study, we aimed to inves-tigate the relationship of the TyG index with demographic characteristics, clinical findings, labora-tory parameters, and mortality in patients admitted to the intensive care unit (ICU) due to COVID-19.
Methods: Between November 2021 and April 2022, a retrospective cross-sectional design was employed to include 88 COVID-19-positive patients with CO-RADS scores of 3 or higher admitted to a tertiary-level ICU. Demographic data, comorbidities, symptoms, laboratory results, thoracic computed tomography (CT) findings, and clinical outcomes were recorded. The TyG index was calculated using the formula Ln[triglyceride (mg/dL) × glucose (mg/dL)/2]. Statistical analyses utilized pa-rametric and nonparametric tests, with significance set at p<0.05.
Results: The mean age of the patients was 74.6±12.9 years, with 54.5% being male. The average TyG index was 4.95±0.35. The TyG index was significantly higher in patients with a history of diabetes melli-tus and cardiovascular disease (p=0.030 and p=0.035). The TyG value was higher in the presence of fever (p=0.033). The mortality rate was 53.4%, but no direct relationship was observed between TyG and mortality. Logistic regression analysis revealed no independent association between the TyG index and mortality (OR=1.32; 95% CI=0.61-2.87; p=0.478). While intubation, vasopressor use, septicemia, and oxygen saturation <90% were significantly associated with mortality, no sig-nificant relationship was found with TyG.
Conclusion: The TyG index appears to be associated with metabolic comorbidities and inflammatory markers in COVID-19 ICU patients; however, it is insufficient as an independent marker for mortality pre-diction. Largerscale studies are required.
Keywords
COVID-19, Insulin resistance, Intensive care, Mortality, Triglyceride-Glucose index
Ethical Statement
Ethical approval was obtained from the Non-Interventional Clinical Research Ethics Committee of Eskisehir Osmangazi University (Decision No: 32, 26/7/2022).
References
- 1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. doi:10.1016/S0140-6736(20)30566-3.
- 2. Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endo-crinol. 2020;8(9):782-92. doi:10.1016/S2213-8587(20)30238-2.
- 3. Guerrero-Romero F, Simental-Mendía LE, González-Ortiz M, Martínez-Abundis E, Ramos-Zavala MG, Hernández-González SO, et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity: comparison with the euglycemichyperinsulinemic clamp. J Clin Endocrinol Metab. 2010;95(7):3347-51. doi:10.1210/jc.2010-0288.
- 4. Liu Q, Zhang Y, Chen S, Xiang H, Ouyang J, Liu H, et al. Association of the triglyceride-glucose index with all-cause and cardiovascular mortality in patients with cardiometabolic syndrome: a national cohort study. Cardiov Diabetol. 2024;23(1):80. doi:10.1186/s12933-024-02152-y.
- 5. Ren H, Yang Y, Wang F, Yan Y, Shi X, Dong K, et al. Association of the insulin resistance marker TyG index with the severity and mortality of COVID-19. Cardiov Diabetol. 2020;19(1):58. doi:10.1186/s12933-020-01035-2.
- 6. Biter HI, Kalyoncuoğlu M, Tosu AR, Çakal S, Apaydın Z, Gümüşdağ A, et al. Prognostic value of the TyG index for in-hospital mortality in nondiabetic COVID-19 patients with myocardial injury. Rev Assoc Med Bras (1992). 2022;68(9):1297-302. doi:10.1590/1806-9282.20220410.
- 7. Chang Y, Jeon J, Song TJ, Kim J. Association of triglyceride-glucose index with prognosis of COVID-19: a population-based study. J Infect Public Health. 2022;15(8):837-44. doi:10.1016/j.jiph.2022.06.014.
- 8. Sharifi-Zahabi E, Nasiri N, Hajizadeh-Sharafabad F, Sharifi M, Saber A. Triglyceride–glucose index and the risk of in-hospital and ICU all-cause mortality: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2025;15(1):8. doi:10.1038/s41387-025-00366-x.
- 9. Prokop M, van Everdingen W, van Rees Vellinga T, Quarles van Ufford H, Stöger L, Beenen L, et al. CO-RADS: a categorical CT assessment scheme for patients suspected of having COVID-19: definition and evaluation. Radiology. 2020;296(2):E97-E104. doi:10.1148/radiol.2020201473.
- 10. Xu H, Mo R, Liu Y, Niu H, Cai X, He P. L-shaped association between triglyceride-glucose body mass index and short-term mortality in ICU patients with sepsisassociated acute kidney injury. Front Med (Lausanne). 2024;11:1500995. doi:10.3389/fmed.2024.1500995.